Observational studyPloS one2026
Integrated microbiomics and metabolomics analysis reveals distinct profiles in carbapenem-resistant Acinetobacter baumannii and Escherichia coli infections in Pancreatitis-associated sepsis.
Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatitis-associated sepsis (PAS) caused by carbapenem-resistant bacteria poses significant clinical challenges. The objective of this research was to examine the microbial and metabolic profiles of individuals with carbapenem-resistant Acinetobacter baumannii (CRAB) and Escherichia coli (CREC) infections using integrated microbiomics and metabolomics approaches.
methodsPeripheral blood samples from 11 PAS patients (8 CRAB, 3 CREC) were analyzed using 16S rDNA gene sequencing and untargeted metabolomics via LC-MS. Microbial diversity, community structure, and differential metabolites were examined between CRAB and CREC groups.
resultsCRAB patients exhibited higher microbial diversity compared to CREC patients. p-Proteobacteria, p-Firmicutes, and p-Cyanobacteria predominated in both patient groups. Significant differences in microbial composition were observed, with p-Proteobacteria more abundant in CRAB and p-Cyanobacteria in CREC samples. g-Enhydrobacter and s-Moraxella osloensis were the biomarkers, significantly higher in CREC patients. Metabolomic analysis revealed 328 differential metabolites between groups, with the majority being downregulated in CRAB. The main categories of identified differential metabolites were amino acids and their derivatives. These differential metabolites were closely related to various metabolic pathways. The most significant metabolic difference between the two patient groups was the level of triglycerides. R-2 Methanandamide and 13-(β-D-glucosyloxy) docosanoic acid showed the highest correlation with g-Enhydrobacter and s-Moraxella osloensis.
conclusionIn PAS patients, s-Moraxella osloensis is a biomarker distinguishing CRAB and CREC infections, correlating with R-2 Methanandamide and 13-(β-D-glucosyloxy) docosanoic acid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.